Skip to main content
Clinical Trials/NCT00928655
NCT00928655
Completed
Phase 4

Continuous Positive Airway Pressure (CPAP) and Acetazolamide for Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude

University of Zurich1 site in 1 country51 target enrollmentJune 2009

Overview

Phase
Phase 4
Intervention
acetazolamide
Conditions
Obstructive Sleep Apnea Syndrome
Sponsor
University of Zurich
Enrollment
51
Locations
1
Primary Endpoint
sleep disordered breathing and oxygenation
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The purpose of the study is to investigate the effect of nasal continuous positive airway pressure in combination with acetazolamide as a treatment for sleep related breathing disturbances in patients with the obstructive sleep apnea syndrome living at low altitude during a sojourn at moderate altitude.

Registry
clinicaltrials.gov
Start Date
June 2009
End Date
November 2009
Last Updated
11 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Obstructive sleep apnea syndrome, successfully on CPAP therapy
  • Residence at low altitude (\< 800 m)
  • Obstructive apnea/hypopnea index \>20/h and a complaint of excessive daytime sleepiness before introduction of CPAP therapy
  • \> 15 oxygen desaturations/h (\> 3% dips) during an ambulatory nocturnal pulse oximetry performed at the end of a 4-night period without CPAP

Exclusion Criteria

  • Sleep disorders other than OSA
  • More than mild cardiovascular disease, unstable cardiovascular disease
  • Any lung disease, pulmonary hypertension
  • Chronic rhinitis
  • Treatment with drugs that affect respiratory center drive (benzodiazepines or other sedatives or sleep inducing drugs, morphine or codeine derivates), stimulants (modafinil, methylphenidate, theophylline)
  • Internal, neurologic or psychiatric disease that interfere with sleep quality
  • Previous intolerance to moderate or low altitude (\< 2600 m)
  • Exposure to altitudes \> 1500m for \> 1 day within the last 4 weeks before the study

Arms & Interventions

acetazolamide

combination of acetazolamide and nocturnal continuous positive airway pressure ventilation

Intervention: acetazolamide

acetazolamide

combination of acetazolamide and nocturnal continuous positive airway pressure ventilation

Intervention: nocturnal continuous positive airway pressure

placebo capsules

combination of placebo and nocturnal continuous positive airway pressure ventilation

Intervention: nocturnal continuous positive airway pressure

placebo capsules

combination of placebo and nocturnal continuous positive airway pressure ventilation

Intervention: placebo

Outcomes

Primary Outcomes

sleep disordered breathing and oxygenation

Time Frame: day 2 and 3 at altitude

Secondary Outcomes

  • sleep quality, vigilance, acute mountain sickness, blood pressure(day 2 and 3 at altitude)

Study Sites (1)

Loading locations...

Similar Trials